Annals of internal medicine · 2026
Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Botteri Edoardo, Holme Øyvind, Løberg Magnus, Bretthauer Michael, Kalager Mette, Randel Kristin Ranheim, Hoff Geir
Аннотация
BACKGROUND: Meta-analyses of randomized trials have shown that sigmoidoscopy screening reduces colorectal cancer (CRC) incidence and death for 15 years.
OBJECTIVE: To report the benefits of sigmoidoscopy after 23 years.
DESIGN: Randomized controlled trial. (NORCCAP [Norwegian Colorectal Cancer Prevention], ClinicalTrials.gov: NCT00119912).
SETTING: Population of Oslo and Telemark County, Norway.
PARTICIPANTS: Persons aged 50 to 64 years without CRC at randomization.
INTERVENTION: Screening with once-only sigmoidoscopy, with or without 1 fecal immunochemical test, or no screening.
MEASUREMENTS: Colorectal cancer incidence and death.
RESULTS: A total of 100 210 persons were randomly assigned, and 98 654 were included in intention-to-screen analyses: 20 552 in the screening group and 78 102 in the no-screening group. Participation with screening was 61.4% in men and 64.7% in women. In men, the 23-year cumulative risk for CRC was 4.3% in the screening group and 6.0% in the no-screening group, corresponding to a risk difference of -1.7 percentage points (95% CI, -2.2 to -1.2 percentage points). In women, the corresponding risks were 4.2% and 4.7%, yielding a risk difference of -0.5 percentage points (CI, -1.0 to -0.01 percentage points). In men, the 23-year cumulative risk for CRC death was 1.4% in the screening group and 2.2% in the no-screening group, corresponding to a risk difference of -0.8 percentage points (CI, -1.1 to -0.5 percentage points). In women, the corresponding risks were 1.3% and 1.4%, yielding a risk difference of -0.1 percentage points (CI, -0.3 to 0.1 percentage points). The effect was strongest for rectosigmoid cancer. The addition of fecal blood testing to sigmoidoscopy did not change screening benefits.
LIMITATION: Follow-up through national registries.
CONCLUSION: Offering sigmoidoscopy screening in Norway reduced CRC incidence more in men than in women and reduced CRC death only in men.
PRIMARY FUNDING SOURCE: Norwegian government and Norwegian Cancer Society.
OBJECTIVE: To report the benefits of sigmoidoscopy after 23 years.
DESIGN: Randomized controlled trial. (NORCCAP [Norwegian Colorectal Cancer Prevention], ClinicalTrials.gov: NCT00119912).
SETTING: Population of Oslo and Telemark County, Norway.
PARTICIPANTS: Persons aged 50 to 64 years without CRC at randomization.
INTERVENTION: Screening with once-only sigmoidoscopy, with or without 1 fecal immunochemical test, or no screening.
MEASUREMENTS: Colorectal cancer incidence and death.
RESULTS: A total of 100 210 persons were randomly assigned, and 98 654 were included in intention-to-screen analyses: 20 552 in the screening group and 78 102 in the no-screening group. Participation with screening was 61.4% in men and 64.7% in women. In men, the 23-year cumulative risk for CRC was 4.3% in the screening group and 6.0% in the no-screening group, corresponding to a risk difference of -1.7 percentage points (95% CI, -2.2 to -1.2 percentage points). In women, the corresponding risks were 4.2% and 4.7%, yielding a risk difference of -0.5 percentage points (CI, -1.0 to -0.01 percentage points). In men, the 23-year cumulative risk for CRC death was 1.4% in the screening group and 2.2% in the no-screening group, corresponding to a risk difference of -0.8 percentage points (CI, -1.1 to -0.5 percentage points). In women, the corresponding risks were 1.3% and 1.4%, yielding a risk difference of -0.1 percentage points (CI, -0.3 to 0.1 percentage points). The effect was strongest for rectosigmoid cancer. The addition of fecal blood testing to sigmoidoscopy did not change screening benefits.
LIMITATION: Follow-up through national registries.
CONCLUSION: Offering sigmoidoscopy screening in Norway reduced CRC incidence more in men than in women and reduced CRC death only in men.
PRIMARY FUNDING SOURCE: Norwegian government and Norwegian Cancer Society.